Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 11/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957240 | 1.00 | SCN9A (0.44) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL29950796 | 0.83 | LMNA (0.35) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL14120573 | 0.82 | RORC (0.39) | CYP2C9 | |
| SCHEMBL16734291 | 0.81 | RORC (0.37) | SCN9ACYP2C9 | |
| SCHEMBL29955039 | 0.79 | ENPP2 (0.34) | CYP2C9 | |
| SCHEMBL365208 | 0.79 | SCN9A (0.47) | SCN9ASCN5ACYP3A4CYP2C9 | |
| SCHEMBL29953456 | 0.78 | ENPP2 (0.40) | CYP3A4CYP2C9 | |
| SCHEMBL1811195 | 0.78 | ENPP2 (0.40) | CYP3A4CYP2C9 | |
| SCHEMBL29956760 | 0.78 | BCHE (0.38) | CYP2C9 | |
| SCHEMBL15599286 | 0.77 | SCN9A (0.45) | SCN9ASCN5ACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| EP-3741757-B1 | DIHYDROINDOLIZINONE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2023-07-26 | — | — | EP | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| CN-111630052-B | Dihydroindazinone derivatives | 第一三共株式会社 | 2023-04-18 | — | — | CN | disclosed |
| US-11530211-B2 | Dihydroindolizinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-20 | — | — | US | disclosed |
| US-20220339260-A1 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2022-10-27 | — | — | US | disclosed |
| EP-3423451-B1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | PROPELLON THERAPEUTICS INC (CA) | 2022-08-17 | — | — | EP | disclosed |
| CN-109195965-B | Inhibitors of WDR5 protein-protein binding | 普罗佩纶治疗公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3998107-A1 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | Tokyo Institute of Technology (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2022-05-03 | — | — | US | disclosed |
| EP-2593432-B1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| WO-2013102826-A1 | N-AMINOSULFONYL BENZAMIDES | PFIZER LIMITED (GB) | 2013-07-11 | — | — | WO | disclosed |
| EP-2593431-A2 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012095781-A1 | INDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007869-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | SCN9A 2475/4885SCN5A 590/4885CYP3A4 4620/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | SCN9A 2475/4885SCN5A 590/4885CYP3A4 4620/4885 |
| US-20130109708-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 20/4885SCN5A 4/4885CYP3A4 567/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 25/4885SCN5A 4/4885CYP3A4 471/4885 |
| US-11530211-B2 | Dihydroindolizinone derivative | INSR, GPR119, IAPP | SCN9A 646/4885SCN5A 63/4885CYP3A4 1933/4885 |
| US-20220339260-A1 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | IAPP, INSR, GPR119 | SCN9A 2973/4885SCN5A 900/4885CYP3A4 637/4885 |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | SCN9A 2475/4885SCN5A 590/4885CYP3A4 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.